Thiazolidinediones (TZDs) Affect Osteoblast Viability and Biomarkers Independently of the TZD Effects on Aromatase

A. Seth, V. Sy, A. Pareek, P. Suwandhi, Z. Rosenwaks, L. Poretsky, D. Seto-Young

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Thiazolidinediones (TZDs) are insulin sensitizers used for treatment of diabetes. We have previously reported that TZDs reduce estrogen synthesis by inhibiting aromatase activity in human granulosa cells (HGC). Multiple clinical trials demonstrated that TZDs increase the risk of fractures in postmenopausal women with type 2 diabetes. We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether TZD inhibition of aromatase plays a role in their effects on bone metabolism. Mouse osteoblasts were cultured with and without HGC, and incubated in a medium with or without testosterone, pioglitazone or rosiglitazone. Cell growth, oleic acid uptake, alkaline phosphatase activity, and osteocalcin production were measured. TZDs inhibited estradiol production by up to 84% in HGC/mouse osteoblast co-cultures. TZDs induced mouse osteoblast death and increased oleic acid uptake. TZDs also inhibited alkaline phosphatase activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031). For all the parameters, there were no significant differences between the osteoblast cultures alone and the HCG/osteoblast co-cultures. TZD effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on aromatase.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalHormone and Metabolic Research
Volume45
Issue number1
DOIs
StatePublished - 2013

Fingerprint

Thiazolidinediones
Aromatase
Osteoblasts
Biomarkers
Granulosa Cells
Cell culture
Osteocalcin
Oleic Acid
Coculture Techniques
Alkaline Phosphatase
rosiglitazone
pioglitazone
Medical problems
Cell growth
Metabolism
Human Activities
Type 2 Diabetes Mellitus
Testosterone
Estradiol
Bone

Keywords

  • bone homeostasis
  • oral antidiabetic drugs
  • osteoblast

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Thiazolidinediones (TZDs) Affect Osteoblast Viability and Biomarkers Independently of the TZD Effects on Aromatase. / Seth, A.; Sy, V.; Pareek, A.; Suwandhi, P.; Rosenwaks, Z.; Poretsky, L.; Seto-Young, D.

In: Hormone and Metabolic Research, Vol. 45, No. 1, 2013, p. 1-8.

Research output: Contribution to journalArticle

Seth, A. ; Sy, V. ; Pareek, A. ; Suwandhi, P. ; Rosenwaks, Z. ; Poretsky, L. ; Seto-Young, D. / Thiazolidinediones (TZDs) Affect Osteoblast Viability and Biomarkers Independently of the TZD Effects on Aromatase. In: Hormone and Metabolic Research. 2013 ; Vol. 45, No. 1. pp. 1-8.
@article{d1d0c190f8a1439e975835f1e13031a9,
title = "Thiazolidinediones (TZDs) Affect Osteoblast Viability and Biomarkers Independently of the TZD Effects on Aromatase",
abstract = "Thiazolidinediones (TZDs) are insulin sensitizers used for treatment of diabetes. We have previously reported that TZDs reduce estrogen synthesis by inhibiting aromatase activity in human granulosa cells (HGC). Multiple clinical trials demonstrated that TZDs increase the risk of fractures in postmenopausal women with type 2 diabetes. We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether TZD inhibition of aromatase plays a role in their effects on bone metabolism. Mouse osteoblasts were cultured with and without HGC, and incubated in a medium with or without testosterone, pioglitazone or rosiglitazone. Cell growth, oleic acid uptake, alkaline phosphatase activity, and osteocalcin production were measured. TZDs inhibited estradiol production by up to 84{\%} in HGC/mouse osteoblast co-cultures. TZDs induced mouse osteoblast death and increased oleic acid uptake. TZDs also inhibited alkaline phosphatase activity (58-75{\%}, p<0.046) and osteocalcin production (52-75{\%}, p<0.031). For all the parameters, there were no significant differences between the osteoblast cultures alone and the HCG/osteoblast co-cultures. TZD effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on aromatase.",
keywords = "bone homeostasis, oral antidiabetic drugs, osteoblast",
author = "A. Seth and V. Sy and A. Pareek and P. Suwandhi and Z. Rosenwaks and L. Poretsky and D. Seto-Young",
year = "2013",
doi = "10.1055/s-0032-1321874",
language = "English (US)",
volume = "45",
pages = "1--8",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "1",

}

TY - JOUR

T1 - Thiazolidinediones (TZDs) Affect Osteoblast Viability and Biomarkers Independently of the TZD Effects on Aromatase

AU - Seth, A.

AU - Sy, V.

AU - Pareek, A.

AU - Suwandhi, P.

AU - Rosenwaks, Z.

AU - Poretsky, L.

AU - Seto-Young, D.

PY - 2013

Y1 - 2013

N2 - Thiazolidinediones (TZDs) are insulin sensitizers used for treatment of diabetes. We have previously reported that TZDs reduce estrogen synthesis by inhibiting aromatase activity in human granulosa cells (HGC). Multiple clinical trials demonstrated that TZDs increase the risk of fractures in postmenopausal women with type 2 diabetes. We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether TZD inhibition of aromatase plays a role in their effects on bone metabolism. Mouse osteoblasts were cultured with and without HGC, and incubated in a medium with or without testosterone, pioglitazone or rosiglitazone. Cell growth, oleic acid uptake, alkaline phosphatase activity, and osteocalcin production were measured. TZDs inhibited estradiol production by up to 84% in HGC/mouse osteoblast co-cultures. TZDs induced mouse osteoblast death and increased oleic acid uptake. TZDs also inhibited alkaline phosphatase activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031). For all the parameters, there were no significant differences between the osteoblast cultures alone and the HCG/osteoblast co-cultures. TZD effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on aromatase.

AB - Thiazolidinediones (TZDs) are insulin sensitizers used for treatment of diabetes. We have previously reported that TZDs reduce estrogen synthesis by inhibiting aromatase activity in human granulosa cells (HGC). Multiple clinical trials demonstrated that TZDs increase the risk of fractures in postmenopausal women with type 2 diabetes. We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether TZD inhibition of aromatase plays a role in their effects on bone metabolism. Mouse osteoblasts were cultured with and without HGC, and incubated in a medium with or without testosterone, pioglitazone or rosiglitazone. Cell growth, oleic acid uptake, alkaline phosphatase activity, and osteocalcin production were measured. TZDs inhibited estradiol production by up to 84% in HGC/mouse osteoblast co-cultures. TZDs induced mouse osteoblast death and increased oleic acid uptake. TZDs also inhibited alkaline phosphatase activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031). For all the parameters, there were no significant differences between the osteoblast cultures alone and the HCG/osteoblast co-cultures. TZD effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on aromatase.

KW - bone homeostasis

KW - oral antidiabetic drugs

KW - osteoblast

UR - http://www.scopus.com/inward/record.url?scp=84872328248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872328248&partnerID=8YFLogxK

U2 - 10.1055/s-0032-1321874

DO - 10.1055/s-0032-1321874

M3 - Article

VL - 45

SP - 1

EP - 8

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 1

ER -